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The RV144 trial, a prime-boost vaccine trial consisting of a canarypox vector vaccine (ALVAC-HIV) 
and the glycoprotein 120 (gp120) AIDSVAX B/E vaccine, showed a vaccine efficacy of 31.2% for the 
prevention of HIV-1 infections over a period of 42 months. As a result, further study to determine 
immune correlates of infection risk was conducted in the trial samples to evaluate vaccine-evoked 
antibody responses, innate immune responses and cellular immune responses. Many FHCRC 
researchers were involved in this large clinical study, including Vaccine and Infectious Disease 
Division’s Dr. Julie McElrath and members of the HIV Vaccine Trials Network Laboratory Program, 
along with Dr. Peter Gilbert and colleagues in the Statistical Center for HIV/AIDS Research and 
Prevention (SCHARP). 
Initially, 17 assay types were selected from 32 pilot assays based on the ability to detect postvaccine 
responses, the uniqueness of these responses, and reproducibility. From there, the antibody and 
cellular assays were narrowed down to six, which were chosen to determine the roles of T-cell, IgG 
antibody and IgA antibody responses in the modulation of infection risk. To determine whether 
immune response variables predicted HIV-1 infection during the 42-month follow-up period, samples 
obtained two weeks after the final immunization were used from 41 vaccinees who became infected 
and from 205 uninfected vaccinees. The statistical analysis was designed to optimize the discovery 
of correlates at the expense of an acceptable risk of false positives and powered to detect only 
strong correlates of infection risk. 
When the six variables were analyzed together in multivariate logistic-regression models, IgG 
avidity, neutralizing antibodies, antibody-dependent cellular toxicity, and the level of HIV-1 envelope 
protein (Env)-specific CD4+ T cells did not significantly predict the HIV-1 infection rate. However, two 
variables correlated significantly with infection risk. The binding of plasma IgA antibodies to Env 
correlated directly with the rate of infection (estimated odds ratio, 1.54 per standard deviation (SD) 
increase; P=0.02; q=0.08); and the binding of IgG antibodies to variable regions 1 and 2 (V1V2) of 
HIV-1 Env proteins correlated inversely with the rate of HIV-1 infection (estimated odds ratio, 0.57 
per SD increase, P=0.02; q=0.08). Neither high levels of Env-specific IgA antibodies or low levels of  
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V1V2 antibodies were associated with higher rates of infection when compared to the placebo 
group, suggesting that vaccine-induced IgA antibodies were not infection-enhancing. 
Taken together, high levels of V1V2 antibodies may have contributed to the RV144 vaccine 
protection against HIV-1 infection, and high levels of Env-specific IgA antibodies may have 
diminished the effects of protective antibodies. Different vaccine candidates may have different 
immune correlates, so continued study of both antibody and cellular responses will be necessary 
towards development of vaccine candidates that can improve on the results of the RV144 clinical 
trial. 
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The estimated cumulative incidence of HIV-1 infection over 
time since the measurement of immune responses at week 
26 is shown for the three response subgroups (IgG 
antibodies binding to V1V2) and for placebo recipients who 
were negative for HIV-1 infection at week 24. 
 
